About Adverum Biotechnologies, Inc. (ADVM) β Dividend Analysis 2026
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Is ADVM a good dividend investment in 2026?
ADVM offers a 45.87% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest β investors should weigh current income against growth alternatives.
ADVM DRIP calculator β what's the difference?
With DRIP on a $10,000 investment over 10 years, your ADVM portfolio grows to $15.70M vs $10.29M without reinvestment. This is the compound interest effect in action.
ADVM dividend growth history & forecast
ADVM has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 45.87%.
Company generates negative FCF ($-93M) β borrowing to pay dividends
Debt Leverage0.0Γ Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA β debt servicing risk is elevated
Earnings Momentum-0.1B β -0.1B β -0.2B
15 / 30 pts
15/30
Net income grew in the latest year β positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut β weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Scoreβ’ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
π ADVM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ADVM.
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
π― ADVM Income Goal & Break-Even
Dividend Break-Even
3yr
Years for dividends to fully repay your ADVM investment of $4.36/share (πΊπΈ US Taxable (15%) Β· 15.00% tax)
$10K invested Β· 10 Years
Dividends earned (DRIP)
$52.5K
Lost to inflation (2.8% CPI)
β$2.5K
Real purchasing power gain
$50.1K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in ADVM for:
Shares needed
14,118
Capital required
$61,554
Monthly income
$2,000
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
π ADVM Dividend Payment Schedule
ADVM pays quarterly β 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
π°
Apr
May
Jun
π°
Jul
Aug
Sep
π°
Oct
Nov
Dec
π°
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
π ADVM vs Healthcare Benchmarks
How ADVM compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yieldβ²+43.07% vs sectorBetter
ADVM
45.87%
avg
2.80%
5Y Dividend CAGRβΌ-6.80% vs sectorBelow avg
ADVM
0.00%
avg
6.80%
Payout Ratioβ²-5.00% vs sectorBetter
ADVM
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ADVM sourced from FMP /financial-growth endpoint β real data, not estimates.
ποΈ ADVM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
A-Award
2025-12-09
500,000
β
β
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
M-Exempt
2025-12-09
150,000
$4.20
$630.0K
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
U-Tender
2025-12-09
25,000
$3.56
$89.0K
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
M-Exempt
2025-12-09
150,000
$4.20
$630.0K
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
D-Return
2025-12-09
200,000
$7.15
$1.43M
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
D-Return
2025-12-09
93,000
$7.50
$697.5K
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
U-Tender
2025-12-09
351,513
$3.56
$1.25M
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
U-Tender
2025-12-09
522,666
$3.56
$1.86M
Fischer Laurent
director, officer: CEO, PRESIDENT AND DIRECTOR
D-Return
2025-12-09
110,420
$10.14
$1.12M
Soparkar Peter
officer: CHIEF OPERATING OFFICER
A-Award
2025-12-09
150,000
β
β
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
π―
Analyst Price Target
Wall Street consensus
Current Price
$4.36
Analyst Target
$4.83
Upside / Downside
+10.8%
Range
$4.00 β $5.50
π‘ If ADVM reaches the analyst target of $4.83, investors buying today at $4.36 would see an effective yield of 41.41% on shares purchased at target price β vs 45.87% at current price.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
π About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ADVM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β